| Literature DB >> 19707854 |
K Panková1, D Rösel, M Novotný, Jan Brábek.
Abstract
Tumor cells exhibit at least two distinct modes of migration when invading the 3D environment. A single tumor cell's invasive strategy follows either mesenchymal or amoeboid patterns. Certain cell types can use both modes of invasiveness and undergo transitions between them. This work outlines the signaling pathways involved in mesenchymal and amoeboid types of tumor cell motility and summarizes the molecular mechanisms that are involved in transitions between them. The focus is on the signaling of the Rho family of small GTPases that regulate the cytoskeleton-dependent processes taking place during the cell migration. The multiple interactions among the Rho family of proteins, their regulators and effectors are thought to be the key determinants of the particular type of invasiveness. Mesenchymal and amoeboid invasive strategies display different adhesive and proteolytical interactions with the surrounding matrix and the alterations influencing these interactions can also lead to the transitions.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19707854 PMCID: PMC2801846 DOI: 10.1007/s00018-009-0132-1
Source DB: PubMed Journal: Cell Mol Life Sci ISSN: 1420-682X Impact factor: 9.261
Fig. 1Different morphologies of the invasive tumor cells. Left mesenchymal morphology of K4 sarcoma cells. Right amoeboid morphology of A3 sarcoma cells (representative modulation contrast image recorded at an invasion depth of 50 μm)
A comparison of the main phenotypic characteristics of the mesenchymal and amoeboid modes of invasiveness
| Mesenchymal | Amoeboid |
|---|---|
| Morphology | |
| Elongated | Rounded |
| Attachment to the ECM | |
| Via integrin clusters creating focal contacts and adhesions | Weak, short-term, integrins diffused in the membrane |
| Migration in the ECM | |
| ECM degradation, remodeling | Proteolysis-independent pushing through the ECM |
| Organization of actin cytoskeleton | |
| Actin meshwork (leading edge), stress fibers (traversing the cell) | Contractile actin cortex |
| Velocity of the locomotion | |
| Low | High |
| Cell membrane extensions | |
| Filopodia and lamellipodia | Intensive blebbing |
Fig. 2Interactions among the components of signaling pathways documented to be involved in the MAT/AMT transitions of cells in a 3D environment. The inhibition of the activity of the proteins highlighted in red was shown to trigger amoeboid to mesenchymal transitions. Inactivation of the proteins depicted in green induces a conversion from the mesenchymal to the amoeboid mode of invasiveness. Mesenchymal to amoeboid transitions were also documented in cells expressing activated Cdc42 (Q61L mutation). Rac, a well-established signaling element essential for mesenchymal movement, is also shown, even though the Rac-dependent morphological transitions were not yet thoroughly documented within the 3D environment. Solid lines direct connections, dashed lines indirect connections
Reported MAT/AMT transitions in 3D environment
| Treatment | Tumor cell line | Original morphology in 3D | Changes observed in 3D environment | Ability to migrate in 2D environment | Other characteristics of the induced phenotype | Reference | ||
|---|---|---|---|---|---|---|---|---|
| Morphology | Ability to migrate | 3D matrix used | ||||||
| Inhibition of proteases (protease inhibitor cocktail) | HT-1080 | Elongated | Rounded | Not stated | Collagen | Not stated | Cortical actin, constriction rings, diffused integrins | [ |
| Smurf1 RNAi | MDA-MB-231 | Elongated | Rounded | Not stated | Matrigel | Impaired | Cortical actin, membrane blebbing, increase of MLC2 phosphorylation at the cell periphery | [ |
| BE | Increased | |||||||
| p53 inactivation (MEFs inactivation, A375P expression of p53H273 mutation) | MEFs | Elongated | Rounded | Increased | Matrigel | Not stated | Cortical actin, membrane blebbing, RhoA activation | [ |
| A375P | Increased | |||||||
| Stathmin inhibition (nonphosphorylable mutation) | HT-1080 | Elongated | Rounded | Increased | Collagen | Not changed | Decrease in MT stability | [ |
| Cdc42 activation (Cdc42-Q61L) | A375P | Elongated | Rounded | Increased | Collagen | Increased | Increase of MLC2 phosphorylation | [ |
| PAK2 OE | A375P | Elongated | Rounded | Not stated | Collagen | Not stated | Increase of MLC2 phosphorylation | [ |
| Rho and ROCK inhibitors (TAT-C3/Y-27632) | A375m2 | Rounded | Elongated | Not changed | Matrigel | Not changed | Loss of blebbing, increased formation of membrane protrusions | [ |
| ARHGAP22 RNAi | A375m2 | Rounded | Elongated | Impaired | Collagen | Not stated | Decrease of MLC2 phosphorylation | [ |
| DOCK10 RNAi | A375m2 | Rounded | Elongated | Increased | Collagen | Increased | Decrease of MLC2 phosphorylation | [ |
| N-WASP RNAi | A375m2 | Rounded | Elongated | Not stated | Collagen | Not stated | No change in MLC2 phosphorylation | [ |
| PAK2 RNAi | A375m2 | Rounded | Elongated | Not stated | Collagen | Not stated | Decrease of MLC2 phosphorylation | [ |
| PDK1 RNAi | A375m2 | Rounded | Elongated | Impaired | In vivo | Impaired | Decreased blebbing, decrease of MLC2 phosphorylation | [ |